■ 刊行論文
|
原著
|
|
1.
|
Takashima K†, Isobe K†, Wakabayashi H†, Kaneko K†, Saiki A†, Matuzawa Y†:
Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer and Autoimmune Diseases.
Cureus
17
(5)
:e85067. doi: 10.7759/cureus.85067
, 2025
|
|
2.
|
Wakabayashi H, Kaneko K, Irie Y, Sakai D, Matsuzawa Y.:
Amikacin liposomal inhalation suspension versus injectable streptomycin in patients with refractory pulmonary Mycobacterium avium complex disease: A single-center, retrospective cohort study.
Medicine
104
(49)
:
, 2025
|
|
3.
|
Karin Furukawa, Kaichi Kaneko, Mai Kawazoe, Kotaro Shikano, Takahiko Sugihara, Toshihiro Nanki:
Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases.
The Journal of rheumatology
52
(9)
:927
-933
, 2025
|
|
総説及び解説
|
|
1.
|
Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, Izumi Irita, Miwa Kanaji, Takahiko Sugihara, Junko Nishio, Toshihiro Nanki:
Comparison of the Efficacy of 12-Month Romosozumab Followed by 24-Month Denosumab Versus 36-Month Denosumab or Risedronate for Glucocorticoid-Induced Osteoporosis in Patients with Rheumatic Diseases: A Randomised Prospective Study.
EMJ Rheumatology
12
(1)
:45
-47
, 2025
|
|
症例報告
|
|
1.
|
Wakabayashi H, Kaneko K, Tanaka E, Ohashi R, Namba K, Iwayanagi M, Sakurai H, Irie Y, Sakai D, Takashima K, Murakami Y, Nishida A, Isobe K, Matsuzawa Y.:
Differentiating respiratory syncytial virus pneumonia from interstitial lung disease associated with systemic sclerosis: A case report.
Medicine
104
(46)
:
, 2025
|
|
■ 学会発表
|
国内学会
|
|
1.
|
杉原 毅彦, 西尾 純子, 脇谷 理沙, 小柴 慶子, 金地 美和, 増岡 正太郎, 渡邉 萌理, 村岡 成, 川添 麻衣, 金子 開知, 入田 泉, 古川 果林, 南木 敏宏:
関節リウマチの病因・病態 加齢に伴う気道細菌叢,リンパ球サブセットの変化と高齢発症関節リウマチの病態との関連.
第69回日本リウマチ学会総会,
福岡,
2025/04
|
|
国際学会
|
|
1.
|
Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, Izumi Irita, Miwa Kanaji, Takahiko Sugihara, Junko Nishio, Toshihiro Nank:
Comparison of the efficacy of 12-month romosozumab followed by 24-month denosumab versus 36-month denosumab or risedronate for glucocorticoid-induced osteoporosis in patients with rheumatic diseases; a randomized prospective study.
ヨーロッパリウマチ学会,
Barcelona, Spain,
2025/06
|
|